Il nostro sito utilizza i cookie. Per continuare la navigazione devi accettare il loro utilizzo.
Accetto
Info
Partner Gruppo Markonet
Non ingoiate il rospo
Cerca |

DA LEGGERE...
'Difendetevi! Manuale di sopravvivenza del consumatore' di Carlo Rienzi - Edizioni Cairo
'DISSANGUATI? La guida pratica per la tutela del consumatore' a cura del Codacons - ED. DE AGOSTINI
SANITA' - Rassegna Stampa
venerdì, 28 novembre 2014
ChannelNewsAsia.com

venerdì, 28 novembre 2014

taly bans Novartis flu vaccine after suspicious deaths






ROME: Italy suspended the use of a flu vaccine made by Swiss pharmaceuticals giant Novartis on Thursday (Nov 27) amid fears it may have caused three deaths. The Italian Pharmaceutical Agency (AIFA) banned the use of two batches of the Fluad vaccine after three people who had received it died and a fourth was taken seriously ill. The victims were two women aged 87 and 79 and a 68-year old man, all of whom died between Nov 12 and 19 in southern Italy, according to Italian media reports. The fourth person, a 92-year old man, is in hospital in a serious condition. "Novartis has been notified by AIFA of the precautionary suspension of two lots of Fluad in Italy following reports of the serious adverse effects events after vaccination. No causal relationship to the vaccine has been established," the Swiss company said. A review of the two batches "have confirmed that they are in conformity with all production and quality standards," it said. Health officials called for calm as news of the ban spread. Italian consumer association Codacons called on the health minister to suspend pro-vaccination campaigns, but AIFA insisted vaccines were "a precious resource and irreplaceable for the prevention of seasonal flu." "We need to make sure that the number of people who get vaccinated does not drop. We have to have faith in vaccines," said AIFA head Sergio Pecorelli, who added that "8,000 people die of seasonal flu" each year. The suspected batches were produced at a Novartis plant in the Tuscan city of Siena. The Swiss company said Fluad had been used since 1997, during which time over 65 million doses have been successfully administered throughout the world, "which confirms the data gathered during clinical studies which involved over 70,000 patients."



Sezioni: Rassegna Stampa, Rassegna Stampa Estera
Aree: SANITA'
Parole chiave: vaccine , fluad, novartis, aifa
Testate: ChannelNewsAsia.com